Title Shine Biopharma, “Bridging the gap between early-stage technology and new drug development” 2017-04-13

GENUV (former Shine Biopharam) featured in the BioSpectator. Excerpt translation is as below.



A new biotech has entered the scene. This company, Shine Biopharma (“ShineBio”) develops drug discovery platforms through open innovation to reduce the risk and cost of new drug development. 

On September 12th, Sung-Ho Han, the CEO of ShineBio, introduced the company’s platform and pipelines during the company presentation at ‘Bio Korea 2017’ which was held in COEX located in Seoul, Samseong-dong 

Han explained that “[I] started this company to develop new drugs and drug discovery platforms through open innovation with an intention to reduce therisk and cost of new drug development. The role of ShineBio is to become a bridge between early-stage technology and drug development so that the early-stage technological innovation at university or hospital research center can be led to successful new drug development.


Han said that “[F]rom 10 years of work experience at Kim & Chang, MEDIPOST and DNALINK, I have learned a lot and now have better understanding in all stages of the new drug development process.” She explained that “[W]e are increasing the value of technology through collaboration with the experts in each stage, by complementing patent and license strategy. 



To view the original article in Korean, please click here

Prev National Assembly Bio-Economy Forum “Korea, To Grow into a Global Top Pharmaceutical Power”
Next Shine Biopharam, ”Aims to achieve commercialization of anti-cancer drug and others”